Patent intelligence · US
US 10472394
Cyclosporine analogue mixtures and their use as immunomodulating agents
Cyclosporine analogue mixtures and their use as immunomodulating agents
Patent details — US 10472394
- Jurisdiction
- US
- Status
- granted
- Grant date
- Nov 12, 2019
- Expiration
- Nov 7, 2039
- Applicant
- AURINIA PHARMACEUTICALS INC.
- Claims
- 25
- CPC classes
- A61K, A61K38/00, A61K38/13, A61K47/10
Quick answer
US 10472394 (Cyclosporine analogue mixtures and their use as immunomodulating agents) is held by AURINIA PHARMACEUTICALS INC.. Status: granted. Granted Nov 12, 2019. Expires Nov 7, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- AURINIA PHARMACEUTICALS INC.
- Grant date
- Expiration
- Claims
- 25
- CPC classes
- A61K, A61K38/00, A61K38/13, A61K47/10, A61K9/0095, A61K9/1075
More from AURINIA PHARMACEUTICALS INC.
Related pharmaceutical patents in our USPTO index.
-
US 11622991
Protocol for treatment of lupus nephritis
granted -
US 10973871
Ophthalmic compositions
granted -
US 10286036
Protocol for treatment of lupus nephritis
granted -
US 10265375
Ophthalmic compositions
granted -
US 9765119
Cyclosporine analogue mixtures and their use as immunomodulating agents
granted -
US 9017725
Topical drug delivery systems for ophthalmic use
granted
Frequently asked questions
What is US patent 10472394?
US 10472394 (Cyclosporine analogue mixtures and their use as immunomodulating agents) is held by AURINIA PHARMACEUTICALS INC.. Status: granted. Granted Nov 12, 2019. Expires Nov 7, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10472394?
AURINIA PHARMACEUTICALS INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 7 pharmaceutical patents for this assignee.
When does US 10472394 expire?
Our index shows an expiration date of Nov 7, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.